RxSight, Inc. (RXST)
- Previous Close
54.92 - Open
55.17 - Bid 52.82 x 100
- Ask 53.00 x 100
- Day's Range
52.65 - 56.40 - 52 Week Range
17.09 - 58.21 - Volume
281,302 - Avg. Volume
401,125 - Market Cap (intraday)
1.954B - Beta (5Y Monthly) 1.22
- PE Ratio (TTM)
-- - EPS (TTM)
-1.41 - Earnings Date May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
62.71
RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
www.rxsight.comRecent News: RXST
Performance Overview: RXST
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RXST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RXST
Valuation Measures
Market Cap
2.03B
Enterprise Value
1.91B
Trailing P/E
--
Forward P/E
151.52
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
21.24
Price/Book (mrq)
12.67
Enterprise Value/Revenue
21.41
Enterprise Value/EBITDA
-46.47
Financial Highlights
Profitability and Income Statement
Profit Margin
-54.57%
Return on Assets (ttm)
-18.82%
Return on Equity (ttm)
-38.85%
Revenue (ttm)
89.08M
Net Income Avi to Common (ttm)
-48.61M
Diluted EPS (ttm)
-1.41
Balance Sheet and Cash Flow
Total Cash (mrq)
127.18M
Total Debt/Equity (mrq)
1.88%
Levered Free Cash Flow (ttm)
-26.55M